Strategic partnerships Leverage collaboration with Harvard Medical School and MIT Biomedical Engineering Center to position Alxerion as a premier exosome technology partner for pharma, enabling co-development and access to academic insights, regulatory support, and credibility to accelerate partner engagements.

Personalized therapies Highlight EXOKIT and patient-specific exosome loading as a differentiator for high-value biologics, targeting pharma and biotech developers seeking precision delivery with reduced systemic exposure, enabling potential licensing or sponsored research deals.

Platform scale Position HTS-ExoPlatform as a cost-effective, scalable discovery and library-building capability to attract partners for exosome library access, small RNA/DNA sequence sourcing, and early-stage screening collaborations across diverse indications.

Early-stage funding Capitalize on a startup with grant-leaning revenue signals and a clear R&D roadmap to attract venture interest and strategic investors looking for high-growth, technically differentiated opportunities in the exosome space.

Targeted outreach Prioritize outreach to biotech and pharma companies with exosome or drug delivery interests, offering co-development, technology licensing, or research collaboration opportunities, leveraging the founders’ academic affiliations for credibility and faster partner validation.